Clinical trial
A Prospective, Single-Arm, Exploratory Study of Retlirafusp Alfa Combined With Chemotherapy as Neoadjuvant Therapy for Thoracic Esophageal Squamous Cell Carcinoma
NCT07618910 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Single-Arm, Exploratory Study of Retlirafusp Alfa Combined With Chemotherapy as Neoadjuvant Therapy for Thoracic Esophageal Squamous Cell Carcinoma
- Lead sponsor
- Tang-Du Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- May 30, 2026
- Completion date
- May 30, 2028
- Enrollment
- 33 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.